Sigyn Therapeutics (SIGY) AI Stock Analysis

Sigyn Therapeutics

(Other OTC:SIGY)

Select Model

Rating:26Underperform

Action:N/A

Date:11/13/24

The overall score reflects significant financial challenges, including persistent net losses, high leverage, and no revenue growth. Technical indicators show mixed signals, with potential short-term upward momentum but risk of being overbought. The valuation is concerning with a negative P/E ratio, suggesting the stock is not a value play. The lack of clear communication in the earnings call adds to the uncertainty. Overall, the stock presents high risk with limited visibility into future improvements.

Positive Factors

Innovative TechnologyThe company's proprietary blood purification technology addresses critical medical needs, offering potential for strong market demand and strategic partnerships in healthcare.

Negative Factors

Financial InstabilityPersistent financial difficulties indicate challenges in achieving profitability and sustainability, posing risks to long-term operational viability and investor confidence.

Sigyn Therapeutics (SIGY) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $151.18K
Dividend Yield: ―
Average Volume (3M): 23.38K
Price to Earnings (P/E): -0.0
Beta (1Y): 0.41
Revenue Growth: ―
EPS Growth: 12.05%
Country: US
Employees: 4
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Sigyn Therapeutics Business Overview & Revenue Model

Company Description

Sigyn Therapeutics, Inc. operates as a therapeutic technology enterprise currently in its development phase. The company's core innovation is Sigyn Therapy, an advanced blood purification system designed to overcome the limitations of existing drugs...

How the Company Makes Money

Sigyn Therapeutics generates revenue primarily through the commercialization of its blood purification technology, which targets hospitals and healthcare providers treating patients with severe inflammatory conditions. The company may also engage in...

Sigyn Therapeutics Technical Analysis

Technical Analysis SentimentNegative

Last Price0.03

Price Trends

50DMA0.03Negative

100DMA0.03Negative

200DMA0.11Negative

Market Momentum

MACD-0.00Positive

RSI47.08Neutral

STOCH30.77Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SIGY, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 47.08 is Neutral, neither overbought nor oversold. The STOCH value of 30.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SIGY.

Sigyn Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SIGY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INDP	51Neutral	$474.57M	-0.44	-302.75%	―	―	81.43%
DRMA	45Neutral	$3.84M	-0.18	-166.67%	―	―	88.77%
TOVX	43Neutral	$7.82M	-0.26	-93.49%	―	―	94.38%
AZTR	42Neutral	$4.66M	-0.06	-205.45%	―	―	78.16%
REVB	41Neutral	$2.29M	-0.08	-100.19%	―	―	95.51%
SIGY	26Underperform	$147.84K	-0.01	57.73%	―	―	12.05%

* Healthcare Sector Average

Performance Comparison

SIGY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SIGY	Sigyn Therapeutics, Inc.	0.03	-1.97	-98.65%
TOVX	Theriva Biologics, Inc.	0.18	-0.11	-38.05%
INDP	Indaptus Therapeutics, Inc.	3.50	0.66	23.24%
REVB	Revelation Biosciences Inc.	4.05	-26.75	-86.85%
DRMA	Dermata Therapeutics, Inc.	0.75	-2.32	-75.47%
AZTR	Azitra Inc	0.84	-3.87	-82.24%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2024

Sigyn Therapeutics AI Stock Analysis